China To Survey Cost And Market Pricing Of Medical Insurance Drugs
This article was originally published in PharmAsia News
In tandem with China's health care reform and national basic medicine system implementation, National Development and Reform Commission recently announced that it will conduct a survey on market prices and production costs of all 1,031 Western medicines and 823 TCMs in the catalogs of national basic medical insurance and work injury insurance. The study includes product costs, market price, tender price, provincial pricing and recorded price. NDRC said that clarification about medicine cost and pricing will help the government adjust its pricing policy in a timely manner. According to Beijing Municipal Commission of Development and Reform, the city has identified Beijing Pharmaceutical, Beijing Yibao Quanxin Pharmacy, Peking University Third Hospital, Beijing No.6 Hospital and Beijing Jinsong Hospital as subjects for the survey. (Click here for more - Chinese Language)
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.